About Biotheus
Biotheus is a Healthcare company based in Zhuhai (China) founded in 2018 by Xiaolin Liu and Joanne Sun, and was acquired by BioNTech in November 2024. Biotheus has raised $14.53 million across 4 funding rounds from investors including BioNTech, General Atlantic and IDG Capital. Its chief executive, as recorded, is Xiaolin Liu. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Developer of antibody-based therapeutics for cancer treatment. The companys candidates include PM8001, PM8003, PM1003, PM 1008, PM 1011, and PM1016 for cancer treatment.
- Headquarters Zhuhai, China
- Founders Xiaolin Liu, Joanne Sun
- Stage Acquired
- SectorsHealthcare
- Website biotheus.com
- Acquired by BioNTech (Nov 2024)
Funding Insights of Biotheus
Biotheus has successfully raised a total of $14.53M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.53M
- Total Rounds 4
- Investors Count 9
All 4 funding rounds of Biotheus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | Seed | – | General Atlantic, IDG Capital | ||
| Jun 2020 | Seed | – | New Alliance Capital | – | |
| Jun 2019 | $14.53M | Seed | – | Shiyu | – |
| Jun 2018 | Seed | – | Highlight Capital | – |
10 investors in total: 10 institutional.
Investors in Biotheus
Biotheus has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include BioNTech, General Atlantic and IDG Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States | |
Venture capital firm | idgcapital.com | New York, United States | ||
Private equity and early-stage venture capital firm investing primarily in Chinese companies | highlightcapital.com | Shanghai, China | ||
| cowincapital.com.cn | ||||
PE firm invests in China | nac-capital.com | Shanghai, China | ||
| huajinct.com | ||||
Shiyu Capital is engaged in equity investment and asset allocation. | shiyucapital.com | Beijing, China | ||
Investments in technology companies are managed by Kunlun Capital. | kunlun-cap.com | Beijing, China | ||
Acquisitions are targeted by CPE as a private equity firm. | cpe-fund.com | Beijing, China | ||
Immunotherapeutics for cancer and other diseases are developed. | 2008 | biontech.com | Mainz, Germany |
Investor details for Biotheus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biotheus
2 people are tracked at Biotheus (2 in leadership).
| Name | Role | Group |
|---|---|---|
Xiaolin Liu | Co-Founder & CEO | Leadership |
Joanne Sun | Co-Founder | Leadership |
Complete people profiles for Biotheus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Biotheus
4 dated milestones of Biotheus across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Biotheus is founded.
- Funding First funding round.
- Funding Latest funding round, Seed,.
- Exit Acquired by BioNTech.
Web traffic of Biotheus
Websites that share an audience with Biotheus (biotheus.com).
Websites whose visitors overlap most with Biotheus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharmaceutical-business-review.com | 100% | #2,626,966 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biotheus
Complete news archive for Biotheus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biotheus
Biotheus was founded in 2018.
Biotheus is headquartered in Zhuhai, China. It is registered at Zhuhai, Guangdong, China.
Xiaolin Liu is the CEO of Biotheus, as recorded in our data. They have also founded this company.
Biotheus is a funded company, having raised a total of $14.53M across 4 funding rounds to date.
Developer of antibody-based therapeutics for cancer treatment. The companys candidates include PM8001, PM8003, PM1003, PM 1008, PM 1011, and PM1016 for cancer treatment.
Biotheus has 10 investors. Key investors include BioNTech, General Atlantic, IDG Capital, Highlight Capital, and Cowin Capital.
Yes. Biotheus was acquired by BioNTech in November 2024.